Clinical-stage biotechnology company TScan Therapeutics, Inc. (TCRX) Thursday announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP and an investment fund advised by Lynx1. The agreement is for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7.5 million shares at a price of $4.00 per pre-funded warrant.
Each warrant will be exercisable to purchase one share of voting common stock at $0.0001 per share, representing a premium of 37%. The offering represents a 34% premium over the 10-day volume weighted average closing price.
The financing is expected to close on or about December 27, 2024.
The $30 million gross proceeds from the sale might be used to fund the company's operations into the first quarter of 2027.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.